ABPI: “Patients can’t afford to wait” for AMR infections research

ABPI responds to Government's announcement of details for supporting pharmaceutical companies’ investments in developing drugs to tackle AMR infections

The Association of the British Pharmaceutical Industry (ABPI) has responded to the Government’s announcement of further details for how it will support pharmaceutical companies’ investments in the development of drugs that will treat antimicrobial resistant (AMR) infections, by saying that patients “can’t afford to wait”.

The NHS will test a first-of-its-kind ‘subscription-style’ payment model that will help incentivise companies to develop new drugs needed to tackle antimicrobial resistant infections.

This announcement follows the launch of the Government’s National Action Plan in January. The ABPI awaits further detail for how the pilot will work in practice.

Dr Sheuli Porkess, Executive Director of Research, Medical and Innovation at the ABPI, said: “Increased resistance to antibiotics is one of the greatest threats to global health we face. [This] announcement is an example of how the UK can lead the world in this fight and hopefully brings us closer to fixing the problems that have hampered investment in antibiotics research for so long.

“Patients can’t afford to wait. Our members are ready to get started, and the sooner we get this pilot up and running, the sooner we can apply what we find to other antimicrobials in development.”